# Pulmonx Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/LUNG/pulmonx-reports-first-quarter-2026-financial-results
Ticker: LUNG
Company: Pulmonx
Source: Pulmonx
Published: 2026-04-29 20:05 EST
Original Source URL: https://investors.pulmonx.com
## Summary

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.

## Article Body
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.
## Recent Company News
- 2026-06-01 20:05 EST — [Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Pulmonx
- 2026-04-29 20:05 EST — [Pulmonx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-first-quarter-2026-financial-results) — Source: Pulmonx
- 2026-04-28 20:05 EST — [Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference](https://biopharmsignal.com/news/LUNG/pulmonx-to-present-at-the-bank-of-america-securities-2026-health-care-conference) — Source: Pulmonx
- 2026-04-15 20:05 EST — [Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026](https://biopharmsignal.com/news/LUNG/pulmonx-to-report-first-quarter-2026-financial-results-on-april-29-2026) — Source: Pulmonx
- 2026-03-04 21:06 EST — [Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Pulmonx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)